

Amniotics Q3 2023 - Rights Issue Foundation for Lung Transplantation Study

Redeye comments on Amniotics' Q3 report, including the rights issue and latest development with the main candidate PulmoStem.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Amniotics Q3 2023 - Rights Issue Foundation for Lung Transplantation Study](#)